First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

A. Carrato | R. Salazar | C. García-Girón | J. García-Foncillas | A. Abad | C. Montagut | B. Massuti | M. Provencio | M. Valladares-Ayerbes | F. Rivera | A. Antón | C. Pericay | R. López | V. Alberola | C. Grávalos | V. Arrazubi | A. Cervantes | A. Oltra | E. Díaz-Rubio | M. Benavides | E. Aranda | C. Martín | R. Vera | J. Remon | J. Gallego | C. Guillén-Ponce | A. Muñoz | M. Safont | J. Sastre | S. Albiol | P. Escudero | A. Viúdez | M. Llanos | A. Salud | H. Manzano | C. Fernandez-martos | P. García-Alfonso | J. Manzano | C. Alonso | J. Viéitez | V. Alonso-Orduña | D. Almenar | R. Dueñas | F. Losa | A. Gómez | V. A. Orduña | P. Alfonso | M. Constenla | A. La Casta | J. Alcaide | G. Durán | A. Galán | A. Yuste | E. Marcuello | R. Afonso | A. Arriví | T. García | S. Casado | E. Barrajón | J. Cassinello | A. Yubero | L. Robles | B. García-Paredes | A. Velasco | M. Chaves | E. Falcó | B. Queralt | E. González | M. Reboredo | M. Valladares | J. L. Puche | J. Tabernero | M. Safont | V. Valenti | A. López-Ladrón | M. Gallén | V. Conde | R. Ferreiro | F. Longo-Muñoz | F. Dorta | E. Jiménez | M. Nogué | A. Ruiz | P. de Prado | M. M. Urena | M. Navalón | J. Vicent | C. López-López | M. J. Ortiz-Morales | M. Gay | L. del Río | J. M. Manzano Mozo | A. J. L. A. V. Alonso A. E. A. F. C. J. L. García J. Abad Manzano Antón Orduña Arrivi Falcó Carrato | J. G. López | Á. Lescure | A. Etxeberría | A. M. G. Tapiador | A. Ruiz | X. Hernández-Yagüe | E. Cabrera | J. Alfaro | J. M. Campos | J. L. M. Valades | M. Centelles | M. J. Gomez | P. Bueso | P. García-Teijido | N. Cardenas | R. Grandez | S. Merino | T. Checa | C. Fernández‐Martos | M. M. Ureña | B. Massutí | José María Viéitez | J. L. López | J. M. Viéitez | J. M. Valades | J. Viéitez | B. Massutí | V. Valentí | C. Fernández-Martos | X. Hernández-Yagüe | J. L. Manzano Mozo

[1]  M. Fassan,et al.  First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study. , 2020 .

[2]  A. Bouvier,et al.  Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG). , 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[3]  F. Brunetti,et al.  Inclusion of Older Patients with Cancer in Clinical Trials: The SAGE Prospective Multicenter Cohort Survey. , 2019, The oncologist.

[4]  A. Ravaud,et al.  Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First‐Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study , 2019, Clinical colorectal cancer.

[5]  W. Mackillop,et al.  Real-world data: towards achieving the achievable in cancer care , 2019, Nature Reviews Clinical Oncology.

[6]  V. Georgoulias,et al.  Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG). , 2019, Journal of geriatric oncology.

[7]  F. Rivera,et al.  First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. , 2018, European journal of cancer.

[8]  O. Bouché,et al.  Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer. , 2018, European journal of cancer.

[9]  T. Wilkins,et al.  Colorectal Cancer Screening and Prevention. , 2018, American family physician.

[10]  F. di Costanzo,et al.  Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study. , 2018, Journal of geriatric oncology.

[11]  L. Zelek,et al.  Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients , 2018, International Journal of Colorectal Disease.

[12]  A. Carrato,et al.  Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  O. Bouché,et al.  Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  A. Carrato,et al.  First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). , 2017, European journal of cancer.

[15]  T. Price,et al.  Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence , 2017, Drugs & Aging.

[16]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Chuanjie Zhao,et al.  Meta-analysis of molecular targetted agents in the treatment of elderly patients with metastatic colorectal cancer: does the age matter? , 2016, Journal of chemotherapy.

[18]  B. Massuti,et al.  Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study , 2015, BMC Cancer.

[19]  C. García-Girón,et al.  Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer , 2015, PloS one.

[20]  A. Hinke,et al.  Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results , 2014, BMC Cancer.

[21]  T. Pavlík,et al.  Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry , 2014, BMC Gastroenterology.

[22]  D. Shin,et al.  Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. , 2013, The Lancet. Oncology.

[23]  R. Simes,et al.  Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  J. Tabernero,et al.  First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. , 2012, The oncologist.

[25]  F. Kabbinavar,et al.  Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies , 2009, Journal of Cancer Research and Clinical Oncology.

[26]  J. Hecht,et al.  Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Joy H. Lewis,et al.  Participation of patients 65 years of age or older in cancer clinical trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.